| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.069 | 0.1 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |